Cargando…

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients

BACKGROUND: Despite widespread use of repeated doses of potent bone-targeting agents (BTA) in oncology patients, relatively little is known about their in vivo effects on bone homeostasis, bone quality, and bone architecture. Traditionally bone quality has been assessed using a trans-iliac bone biop...

Descripción completa

Detalles Bibliográficos
Autores principales: Beltran-Bless, A., Murshed, M., Zakikhani, M., Kuchuk, I., Bouganim, N., Robertson, S., Kekre, N., Vandermeer, L., Li, J., Addison, C.L., Rauch, F., Clemons, M., Kremer, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605385/
https://www.ncbi.nlm.nih.gov/pubmed/34841014
http://dx.doi.org/10.1016/j.bonr.2021.101145
_version_ 1784602165869805568
author Beltran-Bless, A.
Murshed, M.
Zakikhani, M.
Kuchuk, I.
Bouganim, N.
Robertson, S.
Kekre, N.
Vandermeer, L.
Li, J.
Addison, C.L.
Rauch, F.
Clemons, M.
Kremer, R.
author_facet Beltran-Bless, A.
Murshed, M.
Zakikhani, M.
Kuchuk, I.
Bouganim, N.
Robertson, S.
Kekre, N.
Vandermeer, L.
Li, J.
Addison, C.L.
Rauch, F.
Clemons, M.
Kremer, R.
author_sort Beltran-Bless, A.
collection PubMed
description BACKGROUND: Despite widespread use of repeated doses of potent bone-targeting agents (BTA) in oncology patients, relatively little is known about their in vivo effects on bone homeostasis, bone quality, and bone architecture. Traditionally bone quality has been assessed using a trans-iliac bone biopsy with a 7 mm “Bordier” core needle. We examined the feasibility of using a 2 mm “Jamshidi™” core needle as a more practical and less invasive technique. METHODS: Patients with metastatic breast cancer on BTAs were divided according to the extent of bone metastases. They were given 2 courses of tetracycline labeling and then underwent a posterior trans-iliac trephine biopsy and bone marrow aspirate. Samples were analyzed for the extent of tumor invasion and parameters of bone turnover and bone formation by histomorphometry. RESULTS: Twelve patients were accrued, 1 had no bone metastases, 3 had limited bone metastases (LSM) (<3 lesions) and 7 had extensive bone metastases (ESM) (>3 lesions). Most of the primary tumors were estrogen receptor (ER)/progesterone receptor (PR) positive. The procedure was well tolerated. The sample quality was sufficient to analyze bone trabecular structure and bone turnover by histomorphometry in 11 out of 12 patients. There was a good correlation between imaging data and morphometric analysis of tumor invasion. Patients with no evidence or minimal bone metastases had no evidence of tumor invasion. Most had suppressed bone turnover and no detectable bone formation when treated with BTA. In contrast, 6 out of 7 patients with extensive bone invasion by imaging and evidence of tumor cells in the marrow had intense osteoclastic activity as measured by the number of osteoclasts. Of these 7 patients with ESM, 6 were treated with BTA with 5 showing resistance to BTA as demonstrated by the high number of osteoclasts present. 3 of these 6 patients had active bone formation. Based on osteoblast activity and bone formation, 3 out of 6 patients with ESM responded to BTA compared to all 3 with LSM. Compared to untreated patients, all patients treated with BTA showed a trend towards suppression of bone formation, as measured by tetracycline labelling. There was also a trend towards a significant difference between ESM and LSM treated with BTA, highly suggestive of resistance although limited by the small sample size. DISCUSSION: Our results indicate that trans-iliac bone biopsy using a 2 mm trephine shows excellent correlation between imaging assessment of tumor invasion and tumor burden by morphometric analysis of bone tissues. In addition, our approach provides additional mechanistic information on therapeutic response to BTA supporting the current clinical understanding that the majority of patients with extensive bone involvement eventually fail to suppress bone turnover (Petrut B, et al. 2008). This suggests that antiresorptive therapies become less effective as disease progresses.
format Online
Article
Text
id pubmed-8605385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86053852021-11-26 Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients Beltran-Bless, A. Murshed, M. Zakikhani, M. Kuchuk, I. Bouganim, N. Robertson, S. Kekre, N. Vandermeer, L. Li, J. Addison, C.L. Rauch, F. Clemons, M. Kremer, R. Bone Rep Full Length Article BACKGROUND: Despite widespread use of repeated doses of potent bone-targeting agents (BTA) in oncology patients, relatively little is known about their in vivo effects on bone homeostasis, bone quality, and bone architecture. Traditionally bone quality has been assessed using a trans-iliac bone biopsy with a 7 mm “Bordier” core needle. We examined the feasibility of using a 2 mm “Jamshidi™” core needle as a more practical and less invasive technique. METHODS: Patients with metastatic breast cancer on BTAs were divided according to the extent of bone metastases. They were given 2 courses of tetracycline labeling and then underwent a posterior trans-iliac trephine biopsy and bone marrow aspirate. Samples were analyzed for the extent of tumor invasion and parameters of bone turnover and bone formation by histomorphometry. RESULTS: Twelve patients were accrued, 1 had no bone metastases, 3 had limited bone metastases (LSM) (<3 lesions) and 7 had extensive bone metastases (ESM) (>3 lesions). Most of the primary tumors were estrogen receptor (ER)/progesterone receptor (PR) positive. The procedure was well tolerated. The sample quality was sufficient to analyze bone trabecular structure and bone turnover by histomorphometry in 11 out of 12 patients. There was a good correlation between imaging data and morphometric analysis of tumor invasion. Patients with no evidence or minimal bone metastases had no evidence of tumor invasion. Most had suppressed bone turnover and no detectable bone formation when treated with BTA. In contrast, 6 out of 7 patients with extensive bone invasion by imaging and evidence of tumor cells in the marrow had intense osteoclastic activity as measured by the number of osteoclasts. Of these 7 patients with ESM, 6 were treated with BTA with 5 showing resistance to BTA as demonstrated by the high number of osteoclasts present. 3 of these 6 patients had active bone formation. Based on osteoblast activity and bone formation, 3 out of 6 patients with ESM responded to BTA compared to all 3 with LSM. Compared to untreated patients, all patients treated with BTA showed a trend towards suppression of bone formation, as measured by tetracycline labelling. There was also a trend towards a significant difference between ESM and LSM treated with BTA, highly suggestive of resistance although limited by the small sample size. DISCUSSION: Our results indicate that trans-iliac bone biopsy using a 2 mm trephine shows excellent correlation between imaging assessment of tumor invasion and tumor burden by morphometric analysis of bone tissues. In addition, our approach provides additional mechanistic information on therapeutic response to BTA supporting the current clinical understanding that the majority of patients with extensive bone involvement eventually fail to suppress bone turnover (Petrut B, et al. 2008). This suggests that antiresorptive therapies become less effective as disease progresses. Elsevier 2021-10-22 /pmc/articles/PMC8605385/ /pubmed/34841014 http://dx.doi.org/10.1016/j.bonr.2021.101145 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Beltran-Bless, A.
Murshed, M.
Zakikhani, M.
Kuchuk, I.
Bouganim, N.
Robertson, S.
Kekre, N.
Vandermeer, L.
Li, J.
Addison, C.L.
Rauch, F.
Clemons, M.
Kremer, R.
Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
title Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
title_full Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
title_fullStr Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
title_full_unstemmed Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
title_short Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
title_sort histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605385/
https://www.ncbi.nlm.nih.gov/pubmed/34841014
http://dx.doi.org/10.1016/j.bonr.2021.101145
work_keys_str_mv AT beltranblessa histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT murshedm histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT zakikhanim histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT kuchuki histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT bouganimn histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT robertsons histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT kekren histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT vandermeerl histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT lij histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT addisoncl histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT rauchf histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT clemonsm histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients
AT kremerr histomorphometricandmicroarchitecturalanalysisofboneinmetastaticbreastcancerpatients